Protillion Biosciences Hires Hollingsworth as CSO
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Protillion Biosciences hired Robert Hollingsworth as its new chief scientific officer, the hire highlighted in STAT+'s regular weekly personnel-moves column.
- Hollingsworth previously held the same chief scientific officer role at Shoreline Therapeutics before moving to Protillion.
- Before Shoreline, Hollingsworth served at Pfizer as vice president and chief scientific officer of cancer vaccines and immunotherapeutics.
- STAT+ runs the column as a recurring reader-submitted roundup, inviting industry contacts to send in their hires, promotions, and departures.
Why it matters: Protillion has recruited a CSO with deep experience spanning Pfizer's oncology vaccine franchise and a prior biotech CSO seat at Shoreline, bringing established pharma R&D leadership to its pipeline. For biotech watchers tracking executive migration, the move continues the pattern of senior Pfizer scientific talent flowing into smaller venture-backed companies.